{"id":16863,"date":"2020-09-23T08:38:41","date_gmt":"2020-09-23T12:38:41","guid":{"rendered":"https:\/\/medicarereport.org\/?p=16863"},"modified":"2020-09-23T08:38:41","modified_gmt":"2020-09-23T12:38:41","slug":"optumrxs-3-recently-approved-drugs-to-watch","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=16863","title":{"rendered":"OptumRx&#8217;s 3 recently approved drugs to watch"},"content":{"rendered":"<p>(By Maia Anderson for <em>Becker&#8217;s Hospital Review<\/em>)<\/p>\n<p>OptumRx, the pharmacy benefit unit of UnitedHealth Group, recently released a report detailing three drugs that it expects to have a significant impact on the pharmaceutical industry in 2020.\u00a0 Continue reading article <a href=\"https:\/\/www.beckershospitalreview.com\/pharmacy\/optumrx-s-3-recently-approved-drugs-to-watch.html\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-7859\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo-300x200.jpg\" alt=\"\" width=\"300\" height=\"200\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo-300x200.jpg 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo-768x512.jpg 768w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo-1024x682.jpg 1024w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo.jpg 1300w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Maia Anderson for Becker&#8217;s Hospital Review) OptumRx, the pharmacy benefit unit of UnitedHealth Group, recently released a report detailing<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-16863","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16863"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16863\/revisions"}],"predecessor-version":[{"id":16864,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16863\/revisions\/16864"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}